• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HDAC10与非小细胞肺癌患者的PD-L1表达及不良预后呈正相关。

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.

作者信息

Liu Xiaomei, Wang Yuxi, Zhang Rong, Jin Ting, Qu Liangliang, Jin Qianwen, Zheng Jiasu, Sun Jiaqi, Wu Ziqing, Wang Linxi, Liu Tianxu, Zhang Yinxu, Meng Xiao, Wang Ying, Wei Ning

机构信息

Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

Department of Medicine, Jinzhou Medical University, Jinzhou, China.

出版信息

Front Oncol. 2020 Apr 21;10:485. doi: 10.3389/fonc.2020.00485. eCollection 2020.

DOI:10.3389/fonc.2020.00485
PMID:32373519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7186423/
Abstract

Currently, non-small cell lung carcinoma (NSCLC) is a major worldwide health problem. Meanwhile accumulating evidence indicates that histone deacetylase (HDAC) activation could induce PD-L1 expression in various types of cancer, especially in myeloma and B-cell lymphomas. Therefore, we hypothesized that high-level expression of HDAC10 is associated with PD-L1 induction and poor prognosis in patients with NSCLC. In total 180 NSCLC patients receiving complete pulmonary resection and systematic lymph node dissection were enrolled from April 2004 to August 2009. The patients with integrated clinicopathological records were followed up. The expression level of HDAC10 and PD-L1 in tissue samples was determined by immunohistochemistry. We observed that HDAC10 expression in lung cancer tissue is significantly higher than that in corresponding para-cancer tissue. Moreover, HDAC10 expression positively correlated with the expression level of PD-L1 ( = 0.213, < 0.05) in NSCLC patients. Subgroup, multivariate analysis showed that the expression level of HDAC10 can be an independent prognostic factor and high-level expression of HDAC10 indicated poor overall survival for pulmonary carcinoma ( = 0.540, < 0.001). Our findings suggest that the expression level of HDAC10 is positively associated with PD-L1 expression and may predict the outcome of patients with NSCLC.

摘要

目前,非小细胞肺癌(NSCLC)是一个全球性的主要健康问题。与此同时,越来越多的证据表明,组蛋白去乙酰化酶(HDAC)激活可诱导多种类型癌症中程序性死亡受体配体1(PD-L1)的表达,尤其是在骨髓瘤和B细胞淋巴瘤中。因此,我们推测HDAC10的高表达与NSCLC患者的PD-L1诱导及预后不良有关。2004年4月至2009年8月,共纳入180例接受了全肺切除及系统性淋巴结清扫的NSCLC患者。对具有完整临床病理记录的患者进行随访。通过免疫组织化学法测定组织样本中HDAC10和PD-L1的表达水平。我们观察到肺癌组织中HDAC10的表达明显高于相应癌旁组织。此外,在NSCLC患者中,HDAC10表达与PD-L1表达水平呈正相关( = 0.213, < 0.05)。亚组多因素分析显示,HDAC10表达水平可作为独立的预后因素,HDAC10高表达提示肺癌患者总生存期较差( = 0.540, < 0.001)。我们的研究结果表明,HDAC10表达水平与PD-L1表达呈正相关,可能预测NSCLC患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/bfe51ec1217e/fonc-10-00485-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/c01cb75041a5/fonc-10-00485-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/95a6e3508c99/fonc-10-00485-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/1fa0f2d0a4ca/fonc-10-00485-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/241c5153c51c/fonc-10-00485-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/bfe51ec1217e/fonc-10-00485-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/c01cb75041a5/fonc-10-00485-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/95a6e3508c99/fonc-10-00485-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/1fa0f2d0a4ca/fonc-10-00485-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/241c5153c51c/fonc-10-00485-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b09/7186423/bfe51ec1217e/fonc-10-00485-g0005.jpg

相似文献

1
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.HDAC10与非小细胞肺癌患者的PD-L1表达及不良预后呈正相关。
Front Oncol. 2020 Apr 21;10:485. doi: 10.3389/fonc.2020.00485. eCollection 2020.
2
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.TLR4在非小细胞肺癌中的表达与接受肺切除术患者的PD-L1及不良预后相关。
Front Immunol. 2017 Apr 21;8:456. doi: 10.3389/fimmu.2017.00456. eCollection 2017.
3
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.评估非小细胞肺癌中的PDL-1和PD-1:一种新型免疫评分方法。
Clin Lung Cancer. 2017 Mar;18(2):220-233.e8. doi: 10.1016/j.cllc.2016.09.009. Epub 2016 Oct 5.
4
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.非小细胞肺癌中PD-1和PD-L1的表达表明在特定亚组中预后良好。
PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.
5
PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.程序性死亡配体1(PD-L1)是有中度/重度吸烟史且血清鳞状细胞癌抗原(SCCA)水平升高的非小细胞肺癌(NSCLC)切除患者的一种预后生物标志物。
J Cancer. 2017 Sep 15;8(16):3251-3260. doi: 10.7150/jca.21118. eCollection 2017.
6
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.组蛋白去乙酰化酶10(HDAC10)的表达与DNA错配修复基因相关,是结肠癌预后良好的一个预测指标。
Oncol Lett. 2017 Oct;14(4):4923-4929. doi: 10.3892/ol.2017.6818. Epub 2017 Aug 24.
7
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.组蛋白去乙酰化酶10表达降低预示着胃癌患者预后不良。
Int J Clin Exp Pathol. 2014 Aug 15;7(9):5872-9. eCollection 2014.
8
Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.PD-L1 和 c-Myc 在非小细胞肺癌中的表达及临床意义。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2663-2674. doi: 10.1007/s00432-019-03025-8. Epub 2019 Sep 20.
9
Co-expression of PD-L1 and HIF-1α predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.PD-L1与HIF-1α的共表达预示非小细胞肺癌患者术后预后不良。
J Cancer. 2021 Feb 2;12(7):2065-2072. doi: 10.7150/jca.53119. eCollection 2021.
10
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.程序性死亡配体1(PD-L1)表达作为非鳞状非小细胞肺癌患者的不良预后因素
Oncotarget. 2017 Apr 11;8(35):58457-58468. doi: 10.18632/oncotarget.17022. eCollection 2017 Aug 29.

引用本文的文献

1
Histone deacetylases 10 as a prognostic biomarker correlates with tumor microenvironment and therapy response in colorectal cancer.组蛋白去乙酰化酶10作为一种预后生物标志物与结直肠癌的肿瘤微环境及治疗反应相关。
World J Gastroenterol. 2025 Jul 14;31(26):108662. doi: 10.3748/wjg.v31.i26.108662.
2
Periplocin Targets HDAC10 to Inhibit NF-κB Signaling and Induce Apoptosis in Myeloid Leukemia Cells.杠柳毒苷靶向组蛋白去乙酰化酶10以抑制核因子κB信号通路并诱导髓系白血病细胞凋亡。
J Cancer. 2025 Jun 23;16(9):2970-2983. doi: 10.7150/jca.113591. eCollection 2025.
3
Discovery of a Novel Selective PAK1/HDAC6/HDAC10 Inhibitor ZMF-25 that Induces Mitochondrial Metabolic Breakdown and Autophagy-Related Cell Death in Triple-Negative Breast Cancer.

本文引用的文献

1
Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer.PD-1/PD-L1 在非小细胞肺癌中的分子调控网络。
Pathol Res Pract. 2020 Apr;216(4):152852. doi: 10.1016/j.prp.2020.152852. Epub 2020 Feb 5.
2
Histone deacetylase 10 knockout activates chaperone-mediated autophagy and accelerates the decomposition of its substrate.组蛋白去乙酰化酶 10 敲除激活伴侣介导的自噬并加速其底物的分解。
Biochem Biophys Res Commun. 2020 Feb 26;523(1):246-252. doi: 10.1016/j.bbrc.2019.12.048. Epub 2019 Dec 18.
3
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
新型选择性PAK1/HDAC6/HDAC10抑制剂ZMF-25的发现,其可诱导三阴性乳腺癌中的线粒体代谢崩溃和自噬相关细胞死亡
Research (Wash D C). 2025 Apr 29;8:0670. doi: 10.34133/research.0670. eCollection 2025.
4
MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer.MS275通过上调程序性死亡受体配体1(PD-L1)诱导肿瘤免疫抑制,并增强抗程序性死亡蛋白1(PD-1)免疫疗法在结直肠癌中的疗效。
Cancer Immunol Immunother. 2025 Mar 17;74(5):150. doi: 10.1007/s00262-025-04004-4.
5
HDAC10 and its implications in Sézary syndrome pathogenesis.组蛋白去乙酰化酶10及其在蕈样肉芽肿发病机制中的意义。
Front Cell Dev Biol. 2025 Jan 31;13:1480192. doi: 10.3389/fcell.2025.1480192. eCollection 2025.
6
HDAC10 inhibits non-small-cell lung cancer cell ferroptosis through the microRNA-223-5p-SLC7A11 axis.组蛋白去乙酰化酶10通过微小RNA-223-5p-SLC7A11轴抑制非小细胞肺癌细胞铁死亡。
Toxicol Res (Camb). 2024 Oct 13;13(5):tfae164. doi: 10.1093/toxres/tfae164. eCollection 2024 Oct.
7
PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression.胸腺上皮肿瘤的肿瘤细胞和免疫细胞中PD-L1的表达:与疾病特征及HDAC表达的相关性
Biomedicines. 2024 Mar 31;12(4):772. doi: 10.3390/biomedicines12040772.
8
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.从免疫检查点到治疗方法:了解免疫检查点调控以及天然产物和传统医学对肺癌免疫检查点和免疫治疗的影响。
Front Immunol. 2024 Feb 15;15:1340307. doi: 10.3389/fimmu.2024.1340307. eCollection 2024.
9
A polyamine metabolism risk signature for predicting the prognosis and immune therapeutic response of kidney cancer.一种用于预测肾癌预后和免疫治疗反应的多胺代谢风险特征
Transl Cancer Res. 2023 Oct 31;12(10):2477-2492. doi: 10.21037/tcr-23-344. Epub 2023 Oct 24.
10
The role of altered protein acetylation in neurodegenerative disease.蛋白质乙酰化改变在神经退行性疾病中的作用。
Front Aging Neurosci. 2023 Jan 4;14:1025473. doi: 10.3389/fnagi.2022.1025473. eCollection 2022.
帕博利珠单抗联合伏立诺他治疗晚期/转移性非小细胞肺癌的 I/ Ib 期研究。
Clin Cancer Res. 2019 Nov 15;25(22):6623-6632. doi: 10.1158/1078-0432.CCR-19-1305. Epub 2019 Aug 13.
4
Novel targets for the treatment of relapsing multiple myeloma.治疗复发性多发性骨髓瘤的新靶点。
Expert Rev Hematol. 2019 Jul;12(7):481-496. doi: 10.1080/17474086.2019.1624158. Epub 2019 Jun 3.
5
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.选择性 HDAC6 抑制剂通过减少肿瘤细胞中巨噬细胞的抗炎表型和抑制性免疫蛋白的下调,改善抗 PD-1 免疫检查点阻断治疗。
Sci Rep. 2019 Apr 16;9(1):6136. doi: 10.1038/s41598-019-42237-3.
6
Systematic Multiomics Analysis of Alterations in C1QBP mRNA Expression and Relevance for Clinical Outcomes in Cancers.C1QBP mRNA表达改变的系统多组学分析及其与癌症临床结局的相关性
J Clin Med. 2019 Apr 15;8(4):513. doi: 10.3390/jcm8040513.
7
Silencing of lncRNA AFAP1-AS1 Inhibits Cell Growth and Metastasis in Clear Cell Renal Cell Carcinoma.长链非编码 RNA AFAP1-AS1 沉默抑制肾透明细胞癌细胞生长和转移。
Oncol Res. 2019 Jun 21;27(6):653-661. doi: 10.3727/096504018X15420748671075. Epub 2019 Mar 4.
8
Effect of adoptive transfer of CD4CD25Foxp3 Treg induced by trichostatin A on the prevention of spontaneous abortion.三氟乙酰螺旋霉素 A 诱导的 CD4CD25Foxp3 Treg 过继转移对预防自然流产的影响。
J Reprod Immunol. 2019 Feb;131:30-35. doi: 10.1016/j.jri.2018.12.002. Epub 2018 Dec 26.
9
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.癌症免疫治疗中 PD-L1 调控的生化方面。
Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 1.
10
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.靶向组蛋白去乙酰化酶的天然和合成药物:一种新兴的抗癌策略。
Nutrients. 2018 Jun 6;10(6):731. doi: 10.3390/nu10060731.